Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | SOLAR-1: alpelisib plus fulvestrant for advanced breast cancer

Fabrice André • 20 Oct 2018
ESMO 2018
Breast Cancer Alpelisib Fulvestrant
SOLAR-1

The latest from SOLAR-1 (NCT02437318), assessing alpelisib plus fulvestrant for advanced breast cancer that progressed on or after aromatase inhibitor treatment., is presented by Fabrice André, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, here at the breast cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, which showcased the latest updates for three major Phase III clinical trials.

More from Fabrice André

KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer
1:17
KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer
Fabrice André • 14 May 2025
DESTINY-Breast07: updated results of first line T-DXd in HER2+ breast cancer
1:18
DESTINY-Breast07: updated results of first line T-DXd in HER2+ breast cancer
Fabrice André • 14 May 2025
Post-progression CDK4/6 inhibitors in breast cancer: a failing strategy?
1:32
Post-progression CDK4/6 inhibitors in breast cancer: a failing strategy?
Fabrice André • 14 May 2025
Evaluating predictors of benefit of CDK4/6 inhibition in breast cancer
0:35
Evaluating predictors of benefit of CDK4/6 inhibition in breast cancer
Fabrice André • 14 May 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals